Table 4.
Detailed results of the multivariable logistic regression model for the primary and secondary endpoints.
| Factor | OR | 95% CI | p-Value |
|---|---|---|---|
| Hyperglycemia | 1.68 | 1.25–2.26 | 0.001 |
| Age | 1.01 | 0.99–1.02 | 0.069 |
| Charlson Comorbidity Index | 1.09 | 1.04–1.14 | <0.001 |
| Coefficient of glucose variation | 0.46 | 0.11–2.0 | 0.3 |
| Percent of glucose in range | 1.01 | 1.0–1.01 | 0.02 |
| Hypoglycemia | 1.95 | 1.20–3.17 | 0.007 |
| Indication for GC administration | |||
| Oncology | 1.35 | 0.92–1.97 | 0.122 |
| Pneumology/Infectiology | 1.39 | 1.04–1.87 | 0.027 |
| Endocrinology 1 | 2.42 | 1.46–4.02 | 0.001 |
| Mean glucose | 1.03 | 1.0–1.07 | 0.050 |
| GC dose 2 | 0.98 | 0.93–1.05 | 0.59 |
For the primary endpoint in patients with hyperglycemia, detailed results for the cofactors are shown. GC: Glucocorticoids. 1 of which 92 (79%) had adrenal insufficiency or stress prophylaxis in chronic GC use. 2 mean GC dose is given as normalized GC dose in mg per prednisolone equivalent per kg per day.